Immunocore (IMCR) Corporate presentation summary

Transformative immunomodulating medicines

• Focus on developing targeted, off-the-shelf bispecific soluble T cell receptor (TCR) therapies that can address over 90% of the human proteome, surpassing the reach of antibody-based therapies.

• Platform spans oncology, infectious diseases, and autoimmune diseases, with distinct ImmTAC, ImmTAV, and ImmTAAI therapeutic classes for each area.

Oncology pipeline and KIMMTRAK performance

• KIMMTRAK is the global standard of care for first-line metastatic uveal melanoma, achieving $107M in Q1 2026 net sales and ≥70% market penetration in major markets.

• Demonstrated a 16% five-year overall survival (OS) rate, doubling the likelihood of survival compared to investigator's choice, with a median OS of 28 months.

• Ongoing Phase 3 trials (TEBE-AM, ATOM) target expanded indications in cutaneous and adjuvant uveal melanoma, with market opportunities up to 6,000 patients annually.

• KIMMTRAK shows durable disease control and activity in cutaneous melanoma, including in patients previously treated with anti-PD1 therapies.

PRAME and brenetafusp portfolio

• Brenetafusp, a PRAME-targeted TCR, is well-tolerated in cutaneous melanoma and ovarian cancer, with most adverse events being mild to moderate and manageable.

• Durable disease control observed in monotherapy and combination settings, with promising disease control rates (DCR) supporting further Phase 3 development.

• Combination with chemotherapy in ovarian cancer enhances antigen presentation and clinical benefit, with DCR up to 69% in combination cohorts.

• Multiple Phase 1/2 and registrational trials ongoing in melanoma, ovarian, and other solid tumors.